Alkermes is seeking a talented individual for a Material Characterization co-op in our Formulation Development Department in Waltham, MA. As a co-op, the selected candidate will support the ongoing work on characterizing the mechanical properties of granular pharmaceutical materials that are paramount to the success of solid dosage forms manufacturing. Specifically, the project focuses on quantifying the flow and compression of pharmaceutical powders. The candidate should have in-depth knowledge of solid mechanics and the current state-of-the-art in this field. The program offers the candidate hands-on experience in various solid-state characterization techniques and the opportunity to gain a fundamental understanding of key aspects of pharmaceutical development processes. Additionally, there will be opportunities to learn and apply statistical analysis and design of experiments.
Basic Qualifications:
- Currently enrolled in an undergraduate program in Mechanical Engineering, Chemical Engineering, Bio-Medical Engineering, or a related discipline.
- Minimum GPA 3.2
- A background in solid mechanics is good to have
Preferred Qualifications:
- Experience with granular material processes
- Proficiency in MATLAB/Python/JMP
- Proficiency with electronic notebook
- Experience working in a pharmaceutical R&D setting
- A background in solid mechanics is good to have
- Experience with good laboratory practices
- Highly motivated and detail-oriented
- Ability to apply scientific principles to design, execute, and interpret experiments
- Team player with good interpersonal skills
- Excellent written and oral communication
Working Conditions: This is a lab-based job position, and the candidate is expected to work full-time in a lab setting.
Physical Requirements: The candidate should be able to work in the lab for at least four hours a day, which may involve lifting up to ten pounds.
About Us
Why join Team Alkermes?
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we are committed to pursuing great science, driven by deep compassion to make a real impact in the lives of patients. Alkermes has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for various neurological disorders, including narcolepsy.
Beyond our important mission of developing medicines to address unmet patient needs, we actively seek to foster a culture of diversity, inclusion and belonging throughout our business. We strive to ensure that all voices are respected and valued, recognizing that our diversity of thought, background and perspective makes us stronger. We are proud to have been recognized as an employer of choice by many national organizations, including being certified as a Great Place to Work in the U.S. in 2024, honored as a Healthiest Employer in both Ohio and Massachusetts in 2023, a Best Place for Working Parents in 2023, and to have received the Bell Seal at the Platinum level for Workplace Mental Health by Mental Health America for three consecutive years (2021-2023).
Alkermes, Inc. is an equal employment opportunity employer and does not discriminate against any qualified applicant or employee because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, gender expression and identity, disability, genetic information, veteran status, military status, application for military service or any other characteristic protected by local, state or federal law. Alkermes also complies with all work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Alkermes is an E-Verify employer.
